Targeting AML with a New Generation of T-Cell Therapies. ft. Brian Atwood, CEO of CERo Therapeutics

Future prospects for CAR-T cell therapy in AMLПодробнее

Current concepts and future developments in T-cell-based immunotherapy of AMLПодробнее

Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and moreПодробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

How Long Can You Have Acute Myeloid Leukemia? - Oncology Support NetworkПодробнее

The challenges in treating AML with CAR T-cell therapyПодробнее

Future role of CAR-T in AMLПодробнее

Allogeneic CD123-targeting CAR T-cell for AML: risks and potentialПодробнее

Finding the right targets for CAR T-cell therapy in AMLПодробнее

Innovations in Cell TherapyПодробнее

SF-3-030: A Function-Selective ERK2 Inhibitor for Targeted Cancer TherapyПодробнее

CAR T-cell therapy: AML adverse events and optimizationПодробнее

Targeted treatment of AML using T cell recruiting antibody constructsПодробнее

AML immunotherapy: patients need to be well informedПодробнее

How will novel agents & CAR-T cells affect the future treatment landscape in B-ALL?Подробнее

BEAT AML: PERSONALIZED TREATMENT FOR DEADLY BLOOD AND BONE MARROW CANCERПодробнее

New strategies in AML: checkpoint inhibitors combined with T-cell engagersПодробнее